Written Description and Enablement Separate Requirements
On March 22, in Ariad Pharmaceuticals v. Eli Lilly & Co., No. 2008-1248, an en banc panel of the U.S. Court of Appeals for the Federal Circuit reaffirmed that § 112, ¶ 1 contains a written description requirement that is separate and distinct from the enablement requirement. The court ruled that the asserted claims of U.S. Patent No. 6,410,516 (the ‘516 patent) are invalid for failure to meet the statutory written description requirement.
Continue Reading...